N-(2-methoxyethyl)-4-nitrobenzamide | 95086-96-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2-methoxyethyl)-4-nitrobenzamide
• 英文别名: N-(2-methoxyethyl)-p-nitrobenzamide；4-nitro-benzoic acid-(2-methoxy-ethylamide)；4-Nitro-benzoesaeure-(2-methoxy-aethylamid)；N-[2-(methyloxy)ethyl]-4-nitrobenzamide；N-(2-Methoxy-aethyl)-4-nitro-benzamid
• CAS: 95086-96-7
• 化学式: C₁₀H₁₂N₂O₄
• mdl: MFCD00751339
• 分子量: 224.216
• InChiKey: GDRBGHXWHDMLEM-UHFFFAOYSA-N

物化性质

• 熔点：
  109-113 °C
• 沸点：
  419.8±30.0 °C(Predicted)
• 密度：
  1.238±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  84.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(2-methoxyethyl)-4-nitrobenzamide 在 calcium chloride 、 锌 作用下， 以 乙醇 、 水 为溶剂， 反应 5.0h， 以52%的产率得到4-氨基-N-(2-甲氧基乙基)苯甲酰胺
  参考文献：
  名称：

  Nishimoto, Sei-ichi; Izukawa, Tsukuru; Haruta, Yasushi, Journal of the Chemical Society. Perkin transactions II, 1984, p. 1959 - 1962

  摘要：

  DOI：
• 作为产物：
  描述：

  甲醇 、 1-(4-硝基苯甲酰基)氮丙啶 在 三氟化硼乙醚 作用下， 反应 0.5h， 生成 N-(2-methoxyethyl)-4-nitrobenzamide
  参考文献：
  名称：

  Nishimoto, Sei-ichi; Izukawa, Tsukuru; Haruta, Yasushi, Journal of the Chemical Society. Perkin transactions II, 1984, p. 1959 - 1962

  摘要：

  DOI：

文献信息

• COMPOUNDS AND METHODS
  申请人：Kallander Lara S.

  公开号：US20120329784A1

  公开（公告）日：2012-12-27

  Disclosed are compounds having the formula: wherein R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are as defined herein, and methods of making and using the same.

  本发明涉及具有以下式的化合物：其中R1，R2，R3，R4，R5和R6如本文所定义，并且涉及制备和使用该化合物的方法。
• AURORA KINASE INHIBITORS AND METHODS OF MAKING AND USING THEREOF
  申请人：Sebti Said M.

  公开号：US20140057913A1

  公开（公告）日：2014-02-27

  Described herein are inhibitors of Aurora kinase and their use in the treatment of cancer. Methods of screening for selective inhibitors of Aurora kinases are also disclosed.

  本文描述了Aurora激酶的抑制剂及其在癌症治疗中的应用。还公开了筛选选择性抑制Aurora激酶的方法。
• [EN] AURORA KINASE INHIBITORS AND METHODS OF MAKING AND USING THEREOF<br/>[FR] INHIBITEURS DE KINASE AURORA ET PROCÉDÉS POUR LES FABRIQUER ET LES UTILISER
  申请人：H LEE MOFFITT CANCER CT AND RES INST

  公开号：WO2012135641A3

  公开（公告）日：2012-12-27
• Development of <i>o</i>-Chlorophenyl Substituted Pyrimidines as Exceptionally Potent Aurora Kinase Inhibitors
  作者：Harshani R. Lawrence、Mathew P. Martin、Yunting Luo、Roberta Pireddu、Hua Yang、Harsukh Gevariya、Sevil Ozcan、Jin-Yi Zhu、Robert Kendig、Mercedes Rodriguez、Roy Elias、Jin Q. Cheng、Saïd M. Sebti、Ernst Schonbrunn、Nicholas J. Lawrence

  DOI：10.1021/jm300334d

  日期：2012.9.13

  The o-carboxylic acid substituted bisanilinopyrimidine 1 was identified as a potent hit (Aurora A IC50 = 6.1 +/- 1.0 nM) from in-house screening. Detailed structure-activity relationship (SAR) studies indicated that polar substituents at the para position of the B-ring are critical for potent activity. X-ray crystallography studies revealed that compound 1 is a type I inhibitor that binds the Aurora kinase active site in a DFG-in conformation. Structure-activity guided replacement of the A-ring carboxylic acid with halogens and incorporation of fluorine at the pyrimidine 5-position led to highly potent inhibitors of Aurora A that bind in a DFG-out conformation. B-Ring modifications were undertaken to improve the solubility and cell permeability. Compounds such as 9m with water-solubilizing moieties at the para position of the B-ring inhibited the autophosphorylation of Aurora A in MDA-MB-468 breast cancer cells.
• Exploration of secondary and tertiary pharmacophores in unsymmetrical N,N′-diaryl urea inhibitors of soluble epoxide hydrolase
  作者：Sampath-Kumar Anandan、Richard D. Gless

  DOI：10.1016/j.bmcl.2010.03.074

  日期：2010.5

  The impact of various secondary and tertiary pharmacophores on in vitro potency of soluble epoxide hydrolase (sEH) inhibitors based on the unsymmetrical urea scaffold 1 is discussed. N,N'-Diaryl urea inhibitors of soluble epoxide hydrolase exhibit subtle variations in inhibitory potency depending on the secondary pharmacophore but tolerate considerable structural variation in the second linker/tertiary pharmacophore fragment. (C) 2010 Elsevier Ltd. All rights reserved.